Rabies Immunoglobulin Treatment Found Safe and Effective

KEDRAB is a human rabies immunoglobulin indicated for passive, transient post-exposure prophylaxis of rabies infection
black german shepard with toy in mouth
(Precision Vaccinations)

An existing rabies treatment, known as KEDRAB, was found by researchers to be safe and effective for patients age 17 and under.

Published in Human Vaccines & Immunotherapeutics on February 9, 2021, these researchers report the first and only pediatric trial of any human rabies immunoglobulin (HRIG) currently available in the USA.

According to the U.S. CDC, someone is treated for possible exposure to rabies every 10 minutes, and once clinical symptoms appear, rabies is virtually 100% fatal, said these researchers.

The current treatment for previously unvaccinated people exposed to rabies is called rabies post-exposure prophylaxis (PEP). 

This treatment includes wound washing, passive neutralization of the virus with infiltration of HRIG into and around the wound site.

Followed by a series of 4 doses of rabies vaccine given over a 2-week timeframe.

And in this latest study carried out by a team of international experts from the USA and Israel, KEDRAB® (HRIG150) has become the first HRIG shown to be safe and effective in children when administered promptly and correctly, as part of the rabies PEP process.

"Despite the large proportion of pediatric cases, limited safety and efficacy data had previously existed for use in pediatric patients," says senior author Dr. James Linakis, from the Warren Alpert Medical School of Brown University.

"Evidence from this KEDRAB US Pediatric Trial confirms that this product addresses an unmet need in children who may have been exposed to rabies, and gives healthcare providers confidence when preventing this deadly condition in countless numbers of young patients across the US," says lead author Dr. Nicholas Hobart-Porter, Pediatric Emergency Physician at the University of Arkansas for Medical Sciences and Arkansas Children's Hospital.

The study looked at a group of 30 trial participants, with suspected or confirmed rabies exposure, over 84 days (as to include a 3-month follow-up). Each participant received PEP. KEDRAB was infiltrated into and around detectable wound site(s) and/or given intramuscularly along with the first of a 4-dose series of rabies vaccine. 

Although the study did not include a placebo control group, placebo treatment of exposed patients is ethically unacceptable due to the near 100% fatality rate of rabies.

No participant showed an active rabies infection at any point, and there were no deaths and no serious adverse events.

While 70% of participants experienced some form of unrelated or related side effect, all of these were mild.

"The study not only confirms the safety and efficacy of KEDRAB but also that KEDRAB could be well tolerated by all patients who participated in this trial," says Novinyo Serge Amega, M.D., head of US Medical Affairs at Kedrion Biopharma. 

"It was the first and only pediatric study of any HRIG available in the United States and, as such, may provide a healthy degree of reassurance for physicians and others who treat children exposed to rabies."

In the US, rabies in humans is extremely rare, with around two deaths on average per year, says the CDC.

The low incidence of human rabies in the US can be attributed to successful pet vaccination and animal control programs, public health surveillance and testing, and availability of post-exposure prophylaxis (PEP) for rabies.

It is important to note that KEDRAB is not licensed outside the United States. Therefore, the authors cannot connect to its use in other nations. PEP’s availability, accessibility, and affordability in developing countries remain a significant component of rabies’ global burden.

Globally, the World Health Organization (WHO) estimates that rabies causes 59,000 human deaths annually in over 150 countries, with 95% of cases occurring in Africa and Asia.

The WHO also says that 40% of the global rabies disease burden occurs in children under 15 years of age and that most encounters of the disease follow a dog bite.

Kamada Ltd. and Kedrion Biopharma Inc provided research funding.

PrecisionVaccinations publishes research-based vaccine news.